Caribou Biosciences, Inc. (CRBU) stock
CRBUNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3078% below fair value
$0.28−0.03 (-8.44%)
Close on Nov 20, 2026Market cap $30.48MP/E –Yield –
Caribou Biosciences free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Caribou Biosciences's free cash flow for the twelve months ending Jun 30, 2026 was -$95.75M. For fiscal 2025 it was -$112.35M. The highest annual figure on record is -$32.89M in fiscal 2019.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$112.35M | – |
| FY2024 | Dec 31, 2024 | -$143.08M | – |
| FY2023 | Dec 31, 2023 | -$104.90M | – |
| FY2022 | Dec 31, 2022 | -$97.42M | – |
| FY2021 | Dec 31, 2021 | -$34.64M | – |
| FY2020 | Dec 31, 2020 | -$33.53M | – |
| FY2019 | Dec 31, 2019 | -$32.89M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$22.79M | – |
| Q1 FY2026 | Mar 31, 2026 | -$27.06M | – |
| Q4 FY2025 | Dec 31, 2025 | -$20.61M | – |
| Q3 FY2025 | Sep 30, 2025 | -$25.30M | – |
| Q2 FY2025 | Jun 30, 2025 | -$28.68M | – |
| Q1 FY2025 | Mar 31, 2025 | -$37.77M | – |
| Q4 FY2024 | Dec 31, 2024 | -$35.99M | – |
| Q3 FY2024 | Sep 30, 2024 | -$33.33M | – |
| Q2 FY2024 | Jun 30, 2024 | -$35.11M | – |
| Q1 FY2024 | Mar 31, 2024 | -$38.65M | – |
| Q4 FY2023 | Dec 31, 2023 | -$23.66M | – |
| Q3 FY2023 | Sep 30, 2023 | -$33.54M | – |
| Q2 FY2023 | Jun 30, 2023 | -$17.74M | – |
| Q1 FY2023 | Mar 31, 2023 | -$29.97M | – |
| Q4 FY2022 | Dec 31, 2022 | -$26.80M | – |
| Q3 FY2022 | Sep 30, 2022 | -$23.73M | – |
| Q2 FY2022 | Jun 30, 2022 | -$24.49M | – |
| Q1 FY2022 | Mar 31, 2022 | -$22.40M | -210.4% |
| Q4 FY2021 | Dec 31, 2021 | -$22.07M | – |
| Q3 FY2021 | Sep 30, 2021 | -$15.90M | – |
| Q2 FY2021 | Jun 30, 2021 | -$16.96M | – |
| Q1 FY2021 | Mar 31, 2021 | $20.29M | – |
| Q4 FY2020 | Dec 31, 2020 | -$8.10M | – |
| Q3 FY2020 | Sep 30, 2020 | -$8.71M | – |
See a number that looks wrong?